US 2019/0167737 A1 · USE OF IAP INHIBITOR AND ONCOLYTIC VIRUS IN PREPARATION OF ANTI-TUMOR DRUG

Abstract

Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.

Claims21

Dependent claims

Use of Caspase activator in the preparation of an anti-tumor synergist for oncolytic virus, wherein the oncolytic virus is selected from at least one alphavirus.

A method for treating a solid or hematological tumor in a subject, comprising:

administering to a subject in need thereof
at least one oncolytic alphavirus;
and
at least one Caspase activator,
thereby treating the tumor.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

16/325,974Filed 18 Aug 2017

Priority

CN 201610688097.918 Aug 2016

Published

6 Jun 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 35/768
Viruses; Subviral particles; Bacteriophages: oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…
A61K 9/48
Medicinal preparations characterised by special physical form: preparations in capsules, e.g. of gelatin, of chocolate

Use of iap inhibitor and oncolytic virus in preparation of anti-tumor drug

Life of this patent

Use of iap inhibitor and oncolytic virus in preparation of anti-tumor drug

Life of this patent

Abstract

Claims21